• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
A.M. Castle & Co.
Acorda Therapeutics, Inc. - Common Stock
Ampd Ventures Inc
Avicanna Inc
Barclays Plc
Blackrock MuniVest Fund II, Inc. Common Stock
Brookmount Expls Inc
Emperor Watch & Jewellery Ltd
Eos Energy Enterprises, Inc. - Warrant
Freedom Holding Corp. - Common Stock
GraniteShares 2x Long TDC Daily ETF
Green River Gold Corp
Hemogenyx Pharmaceuticals Plc.
Integra LifeSciences Holdings Corporation - Common Stock
Intuitive Machines, Inc. - Warrants
Kidoz Inc
Marfrig Global Foods Sa
MultiPlan Corporation Class A Common Stock
ProShares Ultra SpaceX
Psyence Group Inc
Satellos Bioscience Inc. - Common Stock
Schmitt Industries, Inc. - Common Stock
Shift Technologies, Inc. - Class A Common Stock
Standard BioTools Inc. - Common Stock
Star 60
Ximen Mining Corp
Edit Watchlist
Indicators
Dow Jones Industrial Average
NASDAQ Composite
Standard & Poors 500
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

(OP:MSCLF)

0.9230 UNCHANGED
Last Price Updated: 3:51 PM EST, Jan 29, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 0.9230
Bid (Size) N/A (0)
Ask (Size) N/A (0)
Prev. Close 0.9230
Today's Range 0.9230 - 0.9230
52wk Range 0.4419 - 1.000
Shares Outstanding N/A
Dividend Yield N/A
Chart for  (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Satellos Announces First Participant Dosed in Phase 2 Pediatric Study of SAT-3247 for Duchenne Muscular Dystrophy
February 12, 2026
From Satellos Bioscience Inc.
Via Business Wire
News headline image
Satellos Announces Launch of Public Offering in Canada and the United States and Filing of Application to List on Nasdaq
February 05, 2026
From Satellos Bioscience Inc.
Via Business Wire

Performance

52-Week Range 7.7% below 52-week high
0.9230
0.4452W Low 1.0052W High

(MSCLF) traded between $0.44 and $1.00 over the past 52 weeks and last traded at $0.92, 7.7% below its 52-week high.

Past 12 Months
N/A
N/A
N/A
N/A
+78.7%
+72.1%
1W  
1M  
3M  
6M  
YTD +$0.41
1Y +$0.39

MSCLF was +72.1% over the past year, +78.7% year to date.

12 Months vs Market
MSCLF
+72.1%
DIA
+12.3%
SPY
+14.2%
QQQ
+17.0%
IWM
+13.5%

Over the past 12 months MSCLF returned +72.1% versus DIA (Dow) +12.3%, SPY (S&P 500) +14.2%, QQQ (Nasdaq 100) +17.0% and IWM (Russell 2000) +13.5%.

Volume & Liquidity
YTD
177.3K
1Y
132.2K

More News

Read More
News headline image
Satellos Appoints Antoinette Paone as Chief Development Officer and Head of Regulatory Affairs
January 29, 2026
From Satellos Bioscience Inc.
Via Business Wire
News headline image
Satellos Announces Share Consolidation in Connection with Proposed Nasdaq Listing
January 28, 2026
From Satellos Bioscience Inc.
Via Business Wire
News headline image
Satellos Receives Clearance by U.S. FDA and Global Regulators to Initiate Pediatric Phase 2 Study of SAT-3247 for Duchenne Muscular Dystrophy
December 09, 2025
From Satellos Bioscience Inc.
Via Business Wire
News headline image
Satellos to Participate in December Investor Conferences
November 25, 2025
From Satellos Bioscience Inc.
Via Business Wire
News headline image
Satellos Announces Publication in Nature Communications Supporting its Novel Treatment Approach for Duchenne Muscular Dystrophy
November 18, 2025
From Satellos Bioscience Inc.
Via Business Wire
News headline image
Satellos Reports Third Quarter 2025 Results and Announces Appointment of Mark Nawacki to Board of Directors
November 14, 2025
From Satellos Bioscience Inc.
Via Business Wire
News headline image
Satellos to Participate in November Investor Conferences
October 30, 2025
From Satellos Bioscience Inc.
Via Business Wire
News headline image
Satellos Announces First Adult Patient Dosed in LT-001, an Open-Label, Long-Term Follow-Up Study of SAT-3247 in Duchenne Muscular Dystrophy
October 21, 2025
From Satellos Bioscience Inc.
Via Business Wire
News headline image
Satellos Announces New Data Further Demonstrating Safety, Tolerability, and Functional Impact of SAT-3247 in First-in-Human Trial of Adults with Duchenne Muscular Dystrophy
October 10, 2025
From Satellos Bioscience Inc.
Via Business Wire
News headline image
Satellos to Present SAT-3247 Phase 1 Clinical Data in Late-Breaking Poster Session at the 2025 World Muscle Society Congress
September 29, 2025
From Satellos Bioscience Inc.
Via Business Wire
News headline image
Satellos Announces IND Submission to the U.S. FDA and Global Regulatory Filings to Advance a Phase 2 Clinical Trial of SAT-3247 in Children with Duchenne Muscular Dystrophy
September 22, 2025
From Satellos Bioscience Inc.
Via Business Wire
News headline image
Satellos to Participate in Four September Institutional and Retail Investor Conferences
August 21, 2025
From Satellos Bioscience Inc.
Via Business Wire
News headline image
Satellos Reports Second Quarter 2025 Results and Highlights Upcoming Clinical Milestones
August 13, 2025
From Satellos Bioscience Inc.
Via Business Wire
News headline image
Satellos to Present at Canaccord Genuity’s 45th Annual Growth Conference
August 05, 2025
From Satellos Bioscience Inc.
Via Business Wire
News headline image
Satellos Appoints Dr. Wildon Farwell as Chief Medical Officer
July 16, 2025
From Satellos Bioscience Inc.
Via Business Wire
News headline image
Satellos Bioscience Shareholders Elect Two New Board Members
June 18, 2025
From Satellos Bioscience Inc.
Via Business Wire
News headline image
Satellos Bioscience Announces Results of Annual and Special Meeting of Shareholders
June 18, 2025
From Satellos Bioscience Inc.
Via Business Wire
News headline image
Satellos Bioscience to Participate in PPMD’s Annual Conference in Las Vegas
June 16, 2025
From Satellos Bioscience Inc.
Via Business Wire
News headline image
Satellos Announces Encouraging Functional Data from the 28-day Phase 1b Open-Label Trial of SAT-3247 in Adults with Duchenne Muscular Dystrophy
May 22, 2025
From Satellos Bioscience Inc.
Via Business Wire
News headline image
Satellos Reports First Quarter 2025 Results and Highlights Recent Company Progress
May 13, 2025
From Satellos Bioscience Inc.
Via Business Wire
News headline image
Satellos to Present at the CureDuchenne FUTURES National Conference
May 07, 2025
From Satellos Bioscience Inc.
Via Business Wire
News headline image
Satellos to Present at Bloom Burton & Co. Healthcare Investor Conference
April 29, 2025
From Satellos Bioscience Inc.
Via Business Wire
News headline image
Satellos to Participate in Two April Investor Conferences
April 02, 2025
From Satellos Bioscience Inc.
Via Business Wire

Frequently Asked Questions

Is MSCLF publicly traded?
Yes, MSCLF is publicly traded.
What exchange does MSCLF trade on?
MSCLF trades on the OTC Traded
What is the ticker symbol for MSCLF?
The ticker symbol for MSCLF is MSCLF on the OTC Traded
What is the current price of MSCLF?
The current price of MSCLF is 0.9230
When was MSCLF last traded?
The last trade of MSCLF was at 01/29/26 03:51 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap